WO2013147649A3 - Inhibiteurs de la voie de signalisation pi3k/akt/ikk/nf-kb, leurs sels pharmaceutiquement acceptables et compositions les comprenant pour la prévention et le traitement de maladies virales - Google Patents

Inhibiteurs de la voie de signalisation pi3k/akt/ikk/nf-kb, leurs sels pharmaceutiquement acceptables et compositions les comprenant pour la prévention et le traitement de maladies virales Download PDF

Info

Publication number
WO2013147649A3
WO2013147649A3 PCT/RU2013/000243 RU2013000243W WO2013147649A3 WO 2013147649 A3 WO2013147649 A3 WO 2013147649A3 RU 2013000243 W RU2013000243 W RU 2013000243W WO 2013147649 A3 WO2013147649 A3 WO 2013147649A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
treatment
ikk
pi3k
akt
Prior art date
Application number
PCT/RU2013/000243
Other languages
English (en)
Russian (ru)
Other versions
WO2013147649A2 (fr
Inventor
Петр Олегович ФЕДИЧЕВ
Андрей Александрович ВИННИК
Original Assignee
ХОЛИН, Максим Николаевич
НЕСТЕРУК, Владимир Викторович
Открытое Акционерное Общество "Валента Фармацевтика"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ХОЛИН, Максим Николаевич, НЕСТЕРУК, Владимир Викторович, Открытое Акционерное Общество "Валента Фармацевтика" filed Critical ХОЛИН, Максим Николаевич
Publication of WO2013147649A2 publication Critical patent/WO2013147649A2/fr
Publication of WO2013147649A3 publication Critical patent/WO2013147649A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des inhibiteurs de la voie de signalisation PI3K/AKT/IKK/NF-kB, leurs analogues et leurs sels pharmaceutiquement acceptables et des compositions pharmaceutiques les comprenant pour la prévention et le traitement de maladies virales. L'invention est liée à des méthodes de prévention et de traitement de maladies virales utilisant des inhibiteurs de la voie de signalisation PI3K/AKT/IKK/NF-kB, leurs analogues et leurs sels pharmaceutiquement acceptables et les compositions pharmaceutiques les comprenant pour la prévention de maladies virales et la fabrication de médicaments.
PCT/RU2013/000243 2012-03-29 2013-03-25 Inhibiteurs de la voie de signalisation pi3k/akt/ikk/nf-kb, leurs sels pharmaceutiquement acceptables et compositions les comprenant pour la prévention et le traitement de maladies virales WO2013147649A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012112128/15A RU2012112128A (ru) 2012-03-29 2012-03-29 ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
RU2012112128 2012-03-29

Publications (2)

Publication Number Publication Date
WO2013147649A2 WO2013147649A2 (fr) 2013-10-03
WO2013147649A3 true WO2013147649A3 (fr) 2013-12-05

Family

ID=49261364

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2013/000243 WO2013147649A2 (fr) 2012-03-29 2013-03-25 Inhibiteurs de la voie de signalisation pi3k/akt/ikk/nf-kb, leurs sels pharmaceutiquement acceptables et compositions les comprenant pour la prévention et le traitement de maladies virales

Country Status (2)

Country Link
RU (1) RU2012112128A (fr)
WO (1) WO2013147649A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6371838B2 (ja) 2013-07-02 2018-08-08 ライゼン・ファーマシューティカルズ・エスアー Ｐｉ３ｋタンパク質キナーゼ阻害剤、特に、デルタ及び／またはガンマ阻害剤
RU2574007C2 (ru) * 2013-10-16 2016-01-27 Олег Иванович Киселев Инъекционный раствор для лечения вирусных заболеваний, выбранных из гриппа h1n1, h3n2, h5n1, клещевого энцефалита и лихорадки западного нила
CA2936947A1 (fr) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Polytherapie pour le traitement d'infections par le vhb
WO2016069854A1 (fr) * 2014-10-30 2016-05-06 Virginia Commonwealth University Amélioration des effets anti-tumoraux, anti-viraux et anti-protozoaires du 2-amino-n-[4-[5-phénanthrén-2-yl-3-(trifluorométhyl)pyrazol-1-yl] phényl]acétamide (osu-03012) et d'autres médicaments pharmaceutiques
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
CN110859839B (zh) * 2018-08-27 2023-04-18 中国人民解放军军事科学院军事医学研究院 噻唑烷二酮类化合物在制备抗腺病毒药物中的应用
CN111269231B (zh) * 2018-12-04 2023-06-09 安徽中科拓苒药物科学研究有限公司 一种选择性PI3Kδ抑制剂及其用途
CN111793113B (zh) * 2019-04-07 2022-08-05 首都医科大学 二羟甲基四氢咔啉-3-甲酰-The-HGK其合成,活性和应用
CN115135648B (zh) * 2020-02-13 2024-02-09 劲方医药科技(上海)有限公司 二氢萘啶酮类化合物，其制法与医药上的用途
TW202220661A (zh) * 2020-08-07 2022-06-01 德商柏林化學股份公司 包含pi3k抑制劑之經改良醫藥調配物
WO2022106579A1 (fr) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composés pour traiter une maladie associée à la sénescence des macrophages
CN113045559B (zh) * 2021-03-15 2022-05-20 贵州医科大学 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CN113332290B (zh) * 2021-05-11 2023-09-15 湖北工业大学 Voxtalisib化合物在制备抗EV71病毒药物中的应用
WO2023170187A1 (fr) * 2022-03-09 2023-09-14 Technische Universität München INHIBITION DE L'ABSORPTION DE PATHOGÈNES INTRACELLULAIRES PAR DES INHIBITEURS DU COMPLEXE IKK-α/NIK

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025419A1 (en) * 2004-06-25 2006-02-02 Ann Richmond Imidazoquinoxaline compound for the treatment of melanoma
WO2006109196A2 (fr) * 2005-02-04 2006-10-19 Tripep Ab Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc
WO2010049481A1 (fr) * 2008-10-31 2010-05-06 Novartis Ag Combinaison d’un inhibiteur de la phosphatidylinositol-3-kinase (pi3k) et d’un inhibiteur de mtor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025419A1 (en) * 2004-06-25 2006-02-02 Ann Richmond Imidazoquinoxaline compound for the treatment of melanoma
WO2006109196A2 (fr) * 2005-02-04 2006-10-19 Tripep Ab Modeles de souris transgeniques du virus de l'hepatite c (vhc) et identification des therapies pour le vhc
WO2010049481A1 (fr) * 2008-10-31 2010-05-06 Novartis Ag Combinaison d’un inhibiteur de la phosphatidylinositol-3-kinase (pi3k) et d’un inhibiteur de mtor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"«RLS-2004»", RLS, ENTSIKLOPEDIA LEKARSTV, M, vol. 11, 2004, pages 274 - 275 *
"«RLS-2008»", RLS, ENTSIKLOPEDIA LEKARSTV, M., vol. 16, 2007, pages 615, 844 - 845, 852-853 *
"«RLS-2008»", RLS, ENTSIKLOPEDIA LEKARSTV, M., vol. 16, 2007, pages 652 - 655 *
HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, 2006, pages 93 - 98 *
MARJUKI N. ET AL.: "Influenza A virus-induced early activation of ERK and P13K mediated V-ATPase-dependent intracellular pH change required for fusion.", CELL MICROBIOL., vol. 13, no. 4, April 2011 (2011-04-01), pages 587 - 601 *
YEUNG AW ET AL.: "Flavivirus infection induces indoleamine 2,3- dioxygenase in human monocyte-derived macrophages via tumor necrosis factor and NF-kB.", J.LEUKOC.BIOL., vol. 91, no. 4, 2012, pages 657 - 666 *

Also Published As

Publication number Publication date
WO2013147649A2 (fr) 2013-10-03
RU2012112128A (ru) 2013-10-10

Similar Documents

Publication Publication Date Title
WO2013147649A3 (fr) Inhibiteurs de la voie de signalisation pi3k/akt/ikk/nf-kb, leurs sels pharmaceutiquement acceptables et compositions les comprenant pour la prévention et le traitement de maladies virales
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
WO2011086531A3 (fr) Nouveaux agents antipaludiques
IN2014DN09434A (fr)
MY169987A (en) Selective pi3k delta inhibitors
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
WO2013188273A8 (fr) Composition pharmaceutique ophtalmique topique contenant de l'axitinib
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2012174158A3 (fr) Administration de benzodiazépine
WO2013188268A8 (fr) Composition pharmaceutique ophtalmique topique contenant du pazopanib
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
IN2014MN01622A (fr)
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2014002395A (es) Inhibidores de rock suaves, novedosos.
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
WO2013188279A8 (fr) Composition pharmaceutique ophtalmique topique contenant du cediranib
WO2014125504A3 (fr) Compositions pharmaceutiques de fébuxostat
IL250201A0 (en) Administration of erythuran or its salts suitable for pharmaceutical use for the treatment of orthomyxovirus infections
WO2012149295A3 (fr) Procédé d'administration d'anatabine pour traiter des troubles du spectre de l'autisme et des troubles de crise d'épilepsie
WO2012060791A3 (fr) Procédé de production de compositions pharmaceutiques comprenant du cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13769558

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC , EPO FORM 1205N DATED 30.3.2015

122 Ep: pct application non-entry in european phase

Ref document number: 13769558

Country of ref document: EP

Kind code of ref document: A2